| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | 曽我部 正弘 ([徳島大学.キャンパスライフ健康支援センター])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | 岡久 稔也 ([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域総合医療学]/[徳島大学.病院.診療科.内科.消化器内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | 香川 美和子
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 4. | (英) Sei Motoko (日) 勢井 萌都子 (読) せい もとこ
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 5. | 上田 浩之
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 6. | (英) yokoyama reiko (日) 横山 怜子 (読) よこやま れいこ
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 7. | 影本 開三 ([徳島大学.病院.中央診療施設等.がん診療連携センター])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 8. | 田中 宏典 ([徳島大学.病院.先端医科医療開発研究プロジェクト]/[徳島大学.病院.診療科.内科.消化器内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 9. | 喜田 慶史 ([徳島大学.大学院医歯薬学研究部.医学域.先端臨床医学教育研究プロジェクト]/[徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 10. | 中村 文香
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 11. | 友成 哲
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 12. | 岡本 耕一 ([徳島大学.病院.診療科.内科.消化器内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 13. | 宮本 弘志 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学]/[徳島大学.病院.診療科.内科.消化器内科])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 14. | 佐藤 康史 ([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域消化器・総合内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 15. | (英) Nakasono Masahiko (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 16. | 高山 哲治 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.消化器内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Association of variabilities in body mass index and waist circumference with newly achieved remission of metabolic dysfunction-associated fatty liver disease. (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) Although body weight reduction is recommended to ameliorate nonalcoholic fatty liver disease, the effects of body mass index (BMI) and waist circumference (WC) variability on newly achieved remission of metabolic dysfunction-associated fatty liver disease (MAFLD) remain unclear. We aimed to investigate the longitudinal association between BMI and WC variabilities and newly achieved MAFLD remission in both sexes. Among 26,952 patients, 1823 with MAFLD diagnosed by ultrasonography and with >2 health checkups over >2 years from April 2014 to March 2021 were included in this observational cohort study. A generalized estimation equation model analyzed the association between BMI and WC and newly achieved MAFLD remission according to repeated measures at baseline and the most recent stage. Rates of MAFLD remission in male and female patients were 7.4 % and 6.0 %, respectively. Regarding decreased BMI variability, newly achieved MAFLD remission prevalence among the subgroups differed significantly between sexes (p < 0.001). In male patients, a decrease in BMI variability of ≥1.5 kg/m and WC variability of ≥4.2 cm had adjusted odds ratios (ORs) of 5.215 and 2.820, respectively, for newly achieved MAFLD remission. Among female patients, regular exercise and breakfast consumption were accelerating factors for newly achieved MAFLD remission. Non-invasive liver fibrosis scores significantly differed between MAFLD and newly achieved MAFLD remission, including in the subgroups (p < 0.01 and p < 0.001, respectively). Reducing BMI and WC variabilities in male patients and improving lifestyle habits in female patients may accelerate MAFLD remission. (日)
| [継承] |
| ○キーワード (推奨): | 1. | (英) Humans (日) (読)
| [継承] |
| 2. | (英) Male (日) (読)
| [継承] |
| 3. | (英) Female (日) (読)
| [継承] |
| 4. | (英) Body Mass Index (日) (読)
| [継承] |
| 5. | (英) Middle Aged (日) (読)
| [継承] |
| 6. | (英) Non-alcoholic Fatty Liver Disease (日) (読)
| [継承] |
| 7. | (英) Waist Circumference (日) (読)
| [継承] |
| 8. | (英) Adult (日) (読)
| [継承] |
| 9. | (英) Remission Induction (日) (読)
| [継承] |
| 10. | (英) Follow-Up Studies (日) (読)
| [継承] |
| 11. | (英) Prognosis (日) (読)
| [継承] |
| 12. | (英) Metabolic Diseases (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | Diabetes & Metabolic Syndrome (Diabetes India)
(pISSN: 1871-4021, eISSN: 1878-0334)
| ○ISSN (任意): | □ | 1878-0334
ISSN: 1871-4021
(pISSN: 1871-4021, eISSN: 1878-0334) Title: Diabetes & metabolic syndromeTitle(ISO): Diabetes Metab SyndrPublisher: Elsevier Ltd (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 18
| [継承] |
| ○号 (必須): | □ | 5
| [継承] |
| ○頁 (必須): | □ | 103036 103036
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2024年 5月 8日 (令和 6年 5月 8日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.1016/j.dsx.2024.103036 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 38754333 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○WOS (任意): |
| ○Scopus (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) Article.ELocationID: 10.1016/j.dsx.2024.103036 (日)
| [継承] |
| 2. | (英) Article.ELocationID: S1871-4021(24)00097-3 (日)
| [継承] |
| 3. | (英) Article.PublicationTypeList.PublicationType: Journal Article (日)
| [継承] |
| 4. | (英) Article.PublicationTypeList.PublicationType: Observational Study (日)
| [継承] |
| 5. | (英) KeywordList.Keyword: Body mass index (日)
| [継承] |
| 6. | (英) KeywordList.Keyword: Fatty liver disease (日)
| [継承] |
| 7. | (英) KeywordList.Keyword: Metabolic dysfunction (日)
| [継承] |
| 8. | (英) KeywordList.Keyword: Sex (日)
| [継承] |
| 9. | (英) KeywordList.Keyword: Waist circumference (日)
| [継承] |
| 10. | (英) CoiStatement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (日)
| [継承] |